PT - JOURNAL ARTICLE AU - Xiaoqi Yu AU - Dong Wei AU - Wenxin Xu AU - Yulong Li AU - Xinxin Li AU - Xinxin Zhang AU - Jieming Qu AU - Zhitao Yang AU - Erzhen Chen TI - Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third booster dose of vaccination AID - 10.1101/2021.12.17.21267961 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.17.21267961 4099 - http://medrxiv.org/content/early/2021/12/18/2021.12.17.21267961.short 4100 - http://medrxiv.org/content/early/2021/12/18/2021.12.17.21267961.full AB - The Omicron Variant of concern (B.1.1.529) has spread internationally and is raising serious concerns about the reduced vaccine efficacy and the increased risk of reinfection. Here we assessed the serum neutralizing activity using a pseudovirus-based neutralization assay in 292 healthcare workers who had administered a third homologous boosting vaccination 8 to 9 months after completion of the priming two-dose inactivated vaccination to investigate whether the newly identified Omicron variant could escape serum antibody neutralization elicited by the booster vaccination. The third booster dose with BBIBP-CorV lead to a significant rebound in neutralizing immune response against SARS-CoV-2, and the neutralization GMT on day 28 after the third booster dose was 6.1 times higher than the GMT on day 28 after the second dose. The Omicron variant did cause significantly lower neutralization sensitivity compared to the wild-type strain of the booster elicited serum, with about 20.1-fold reduction. Our study demonstrated that a third booster dose of BBIBP-CorV lead to a significant rebound in neutralizing immune response against SARS-CoV-2, while the Omicron variant showed extensive but incomplete escape of the booster elicited neutralization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases (20dz2261100), and a grant from Science and Technology Commission Shanghai Municipality (No. 20JC1410200).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Shanghai Ruijin Hospital gave ethical approval for this work (RJHKY2021-321)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors on reasonable request.